Changing Market Dynamics of Hand foot syndrome/Palmar-plantar erythrodysesthesia syndrome Market in the 7 Major Markets

April 15 20:15 2021
Changing Market Dynamics of Hand foot syndrome/Palmar-plantar erythrodysesthesia syndrome Market in the 7 Major Markets

 

Hand foot syndrome/Palmar-plantar erythrodysesthesia syndrome Market” report has been added to DelveInsight

 

The Hand foot syndrome/Palmar-plantar erythrodysesthesia syndrome market report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome Market

 

Download free sample copy here- https://www.delveinsight.com/sample-request/hand-foot-syndrome-market

 

Hand foot syndrome/Palmar-plantar erythrodysesthesia Syndrome Disease Overview

Palmar-plantar erythrodysesthesia (PPE), also called hand-foot syndrome, is a relatively common dermatologic toxic reaction associated with cytotoxic chemotherapy that can limit the use of such drugs.

 

Hand foot syndrome/Palmar-plantar erythrodysesthesia Syndrome Market: Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

 

Hand foot syndrome/Palmar-plantar erythrodysesthesia Syndrome Key Player

  • Processa Pharmaceuticals

 

Hand foot syndrome/Palmar-plantar erythrodysesthesia Syndrome Drug

  • PCS6422

 

Hand foot syndrome/Palmar-plantar erythrodysesthesia Syndrome Market Report

Painful red swelling of the feet and hands in a patient receiving chemotherapy suggests the diagnosis. A high degree of suspicion is the key to diagnosis in patients receiving chemotherapeutic agents. The problem may also occur in patients with bone marrow transplants, as the clinical and histologic features may mimic cutaneous manifestations of graft-versus-host disease. Dangerous graft-versus-host disease must be differentiated from benign palmar-plantar erythrodysesthesia. Patients with graft-versus-host disease will have progression to other body parts whereas PPE will be limited to hands and feet. Serial biopsies every 3 to 5 days may help in differentiating the two disorders.

 

Hand foot syndrome/Palmar-plantar erythrodysesthesia Syndrome Symptoms

Symptoms of hand-foot syndrome include:

  • Numbness
  • Tingling, Burning, or Itching Sensation
  • Redness (Resembling A Sunburn)
  • Swelling
  • Discomfort
  • Tenderness
  • Rash

 

Hand foot syndrome/Palmar-plantar erythrodysesthesia Syndrome Market Size

The market size of Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome is anticipated to increase during the study period, 2018–2030. The increase in the market size is a direct outcome of the increasing prevalent population of Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome and the expected launch of emerging drugs in the 7MM.

 

Hand foot syndrome/Palmar-plantar erythrodysesthesia Syndrome Treatment Market

Oral dexamethasone has been used in a prophylactic and therapeutic basis in patients with gynecologic malignancies. Drake et al. studied the preventive effect of oral dexamethasone in HFS patients treated with liposomal doxorubicin and a past history of grade 2–4 eruptions. Six patients were retreated without dose reduction and with a tapering oral dexamethasone regimen (8 mg BID on days 1–4, 4 mg BID on day 5, and 4 mg on day 6). All patients continued treatment without dose modification, whereas patient’s not receiving dexamethasone required dose reduction. Although these evidence support that systemic steroids could eliminate symptoms and avoid treatment delays, data regarding the risk-to-benefit ratio are still not sufficient in order to justify routine use of corticosteroids for HFS. In addition, secondary infection such as Staphylococcus aureus should be bear in mind if used with an open wound in skin.

 

Hand foot syndrome/Palmar-plantar erythrodysesthesia Syndrome Market Insights

HFS, although not a life-threatening reaction, it certainly affects QoL and is often a proper dose-risking side effect. With the extension of the use of capecitabine in the adjuvant treatment of colorectal cancer, the incidence of HFS is likely to increase. The prevention and treatment of these reactions are essential to improve the QoL of cancer patients and to avoid unnecessary dose modifications that may affect treatment outcome. It is now clear that even mild cases may be associated with considerable discomfort and dramatic impact on the QoL. Till date, there is a gap in literature on randomized blind studies on therapeutic procedures for HFS or HFSR.

 

Hand foot syndrome/Palmar-plantar erythrodysesthesia Syndrome Market Report Highlights

• In the coming years, Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market

• The companies and academics are working to assess challenges and seek opportunities that could influence Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition 

• Major players are involved in developing therapies for Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome. Launch of emerging therapies will significantly impact the Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome market

• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome

• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Following is the TOC of Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome market report

1. Key Insights

2. Executive Summary of Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome

3. Competitive Intelligence Analysis for Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome

4. Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome: Market Overview at a Glance

5. Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome: Disease Background and Overview

6. Patient Journey

7. Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome Treatment

11. Marketed Products

12. Emerging Therapies

13. Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Why should you buy this report here?

• The report will help in developing business strategies by understanding trends shaping and driving the Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome market

• To understand the future market competition in the Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome market and Insightful review of the key market drivers and barriers

• Organize sales and marketing efforts by identifying the best opportunities for Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan

• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors

• Organize sales and marketing efforts by identifying the best opportunities for Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome market

• To understand the future market competition in the Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome market

 

Contact Us 

Shruti Thakur 

[email protected]  

USA: – +1(919)321-6187 

India:- +91-11-45689769, +91-9650213330

 

 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/